Collaboration creates unmatched capabilities in biopharma industry for real world data generation and insights for market access strategy

CHICAGO, Oct. 8, 2026 /PRNewswire/ — EVERSANA, a leading provider of technology enabled, modern commercialization services to the biopharmaceutical industry, today announced a strategic partnership with Pulse Infoframe, a leader in real-world evidence (RWE) generation and intelligence. Through the partnership, EVERSANA will pair its end-to-end commercialization, market access and health economics and outcomes research (HEOR) expertise with Pulse Infoframe’s proprietary RWE platform and established evidence-generation capabilities, creating a single, continuous evidence engine for pharmaceutical and medical device companies.

The partnership spans the full arc of evidence generation: global site-network and feasibility assessments, registry and natural history study design, and direct data capture from sites and patients, followed by HTA-grade reporting, global value dossiers, and reimbursement strategy. By designing studies to serve regulators, HTA bodies, and commercial teams alike, EVERSANA and Pulse Infoframe help clients carry a single evidence base from first patient enrolled through launch and beyond.

“Real-world evidence has never been more critical as pharmaceutical companies work to develop the best strategies to bring innovative therapies to patients,” said Mark Thierer, Chief Executive Officer, EVERSANA. “By pairing our deep commercial and health economics expertise with Pulse Infoframe’s robust registry expertise in complex conditions, including rare disease and oncology, we can bring unmatched solutions to customers to help improve market access.”

The partnership offers pharmaceutical and medical device manufacturers a seamless solution for evidence generation from study design and global site-network assessments to sophisticated external control arm methods and Health Technology Assessment (HTA)-grade reporting. By uniting complementary strengths, the collaboration delivers compounding gains in efficiency, data quality, and global scale.

“Our platform was built to generate regulatory-grade evidence directly from sites and patients,” said Femida Gwadry-Sridhar (PhD), Chief Executive Officer, Pulse Infoframe. “Working with EVERSANA connects that evidence to the regulatory, reimbursement, and commercial decisions it needs to support, at global scale.”

The partnership will be highlighted by EVERSANA and Pulse Infoframe at ISPOR Europe 2026, November 8-11 in Vienna, Austria.

About EVERSANA^®
EVERSANA^® is the leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners, and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com.

About Pulse Infoframe
Pulse Infoframe is a leading real-world data and evidence generation partner that provides services to clients in the life sciences and healthcare sectors. The company owns and operates its real-world evidence platform, with expertise in registries, natural history studies, and the ability to generate regulatory-grade data directly from sites and patients.

Media Contacts:
Matt Braun
VP, Corporate Communications, EVERSANA
matt.braun@eversana.com 

Femida Gwadry-Sridhar, BSc Pharm, MSc (Epi), PhD
Chief Executive Officer and Founder
femida@pulseinfoframe.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/eversana-and-pulse-infoframe-announce-strategic-partnership-to-deliver-global-real-world-evidence-and-heor-solutions-302901464.html

SOURCE EVERSANA